세계의 해부병리학 시장 규모 : 제품 및 서비스, 용도, 최종 사용자, 지역, 범위 및 예측별, 제품 및 서비스별 시장 규모

Anatomic Pathology Market Size And Forecast

Anatomic Pathology Market size was valued at USD 20.54 Billion in the year 2024, and it is expected to reachUSD 31.92 Billion in 2031, at aCAGR of 5.67% over the forecast period of 2024 to 2031.

Anatomic pathology is a subspecialty of pathology concerned with diagnosing disease through examining organs and tissues.

The field's foundation lies in meticulous gross examination, where the tissue's macroscopic features, size, shape, color, and consistency are meticulously evaluated.

Subsequently, samples are carefully processed and prepared for microscopic analysis. Thin sections are stained with specialized dyes to highlight cellular and structural details.

A pathologist, a physician with extensive training in disease processes and tissue morphology, examines these sections under a microscope. The pathologist meticulously evaluates the microscopic features, searching for characteristic abnormalities that can explain the underlying disease.

Anatomic Pathology Market Dynamics

The key market dynamics that are shaping the anatomic pathology market include:

Key Market Drivers

Rising Burden of Disease:

The increasing incidence of chronic diseases, particularly cancer, is a major driver. Anatomic pathology plays a vital role in diagnosing these conditions, leading to a rising demand for associated services and products.

Growing Focus on Personalized Medicine:

Personalized medicine tailors treatment plans to an individual's specific genetic and molecular makeup. Anatomic pathology plays a crucial role in identifying these targets through advanced techniques, propelling the market growth.

Technological Advancements:

The emergence of digital pathology is transforming the field. Digitalization allows for remote analysis of slides, improves workflow efficiency, and facilitates collaboration among pathologists. Additionally, advancements in immunohistochemistry and molecular testing are enhancing diagnostic accuracy, further driving market expansion.

Increased Government Funding and Reimbursement Initiatives:

Growing government support for healthcare infrastructure and initiatives promoting early disease detection are contributing to market growth. Reimbursement policies that incentivize the use of advanced diagnostic techniques are also playing a significant role.

Key Challenges:

Stringent Regulatory Requirements:

The development and approval of new diagnostic tests and equipment are subject to rigorous regulatory oversight. This can be a lengthy and expensive process, hindering the swift integration of novel technologies into clinical practice.

Workforce Shortages:

A growing global burden of disease coupled with a limited number of qualified pathologists creates a strain on anatomic pathology departments. This shortage can lead to delays in diagnoses and hinder the overall efficiency of the healthcare system.

Integration Costs and Data Security Concerns:

The adoption of advanced technologies like digital pathology necessitates significant infrastructure investments. Additionally, concerns regarding data security and privacy associated with digital pathology workflows need to be addressed effectively.

Reimbursement Pressures:

Healthcare payors are constantly seeking to control costs. While advanced diagnostic tests can improve patient outcomes, obtaining adequate reimbursement for these tests can be challenging, limiting their accessibility in certain settings.

Key Trends:

Surge in Digital Pathology Adoption:

Digital pathology workflows are being increasingly embraced. This technology facilitates remote slide analysis, enabling collaboration among geographically dispersed pathologists and improving workflow efficiency. The ability to store and share digital slides effortlessly fosters improved communication and case consultations.

Integration of Advanced Diagnostics:

Anatomic pathology is witnessing the integration of advanced diagnostic techniques like immunohistochemistry and molecular testing. These advancements offer greater precision in disease diagnosis, allowing for more targeted treatment approaches and improved patient outcomes. This trend is being driven by the growing focus on personalized medicine.

Focus on Workflow Optimization:

Efforts are being directed towards streamlining workflows in anatomic pathology laboratories. This includes automating routine tasks, improving the integration of instruments and software, and adopting digital pathology solutions. These advancements aim to enhance efficiency and reduce turnaround times for diagnoses.

Emerging Markets Offer Growth Potential:

Developing economies like China and India present significant growth opportunities for the anatomic pathology market. This is due to factors such as rising healthcare expenditure, increasing awareness of chronic diseases, and growing investments in healthcare infrastructure.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Anatomic Pathology Market Regional Analysis

Here is a more detailed regional analysis of the anatomic pathology market:

North America:

North America currently holds the dominant position in the global anatomic pathology market, and its leadership is expected to continue for the foreseeable future.

The region boasts a well-established healthcare system with a concentration of leading companies in the anatomic pathology space.

Government agencies in North America actively support initiatives related to pathologist training programs and early disease detection programs.

Hospitals and clinical laboratories in North America are generally well-equipped with advanced technology and infrastructure. This robust infrastructure facilitates the seamless integration of novel diagnostic tools and techniques.

The growing incidence of chronic diseases, particularly cancer, in North America fuels the demand for anatomic pathology services.

Asia Pacific:

The Asia Pacific (APAC) region represents a growing market for anatomic pathology, exhibiting significant growth potential.

Similar to global trends, APAC experiences a growing prevalence of chronic diseases, particularly cancer. This necessitates a surge in diagnostic procedures, driving demand for anatomic pathology services and products.

Rapid population aging in many APAC countries translates into a higher risk of chronic diseases, further amplifying the need for advanced diagnostic tools.

Governments across APAC are increasingly investing in healthcare infrastructure development. This includes the establishment of new hospitals and laboratories equipped with modern technology, fostering the adoption of advanced anatomic pathology techniques.

Disposable incomes are rising in many APAC countries, leading to increased healthcare expenditure. This willingness to spend on healthcare fuels the market for anatomic pathology services and technologies.

Anatomic Pathology Market Segmentation Analysis

The Anatomic Pathology Market is segmented based on Product And Service, Application, End-User, And Geography.

Anatomic Pathology Market, By Product And Service

• Instruments
• Consumables
• Services

Based on Product & Service, the market is divided into instruments, consumables, and services. The service segment dominates the market with the largest market share in 2019 and is expected to register the highest CAGR during the forecast period. This dominance is attributed to factors such as the availability of reimbursement for diagnostic tests, rapid growth in the geriatric population, and increasing incidence of cancer and other chronic diseases.

Anatomic Pathology Market, By Application

• Disease Diagnosis
• Drug Discovery And Development
• Others

Based on Application, the market is segmented into disease diagnosis, drug discovery and development, and others. In 2019, the disease diagnosis segment held the largest market share. This growth can be attributed to the rapid increase in the geriatric population and the rising incidence of cancer and other chronic diseases.

Anatomic Pathology Market, By End-User

• Hospitals
• Diagnostic Laboratories
• Research Laboratories
• Others

Based on end-user, the market is segmented into hospitals, diagnostic laboratories, research laboratories, and others. Diagnostic laboratories, followed by hospitals, have been dominating the market in terms of market share.

Anatomic Pathology Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of The World

Based on Geography, the anatomic pathology market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest market share, followed by Europe. The major factors driving the growth in the Anatomic Pathology Market in these regions include easy access to advanced technologies, government initiatives for cancer patient screening, favorable reimbursement scenarios for Anatomic Pathology Diagnostic Tests, increased healthcare expenditure, and the presence of high-quality infrastructure in hospitals and clinical laboratories.

Key Players

• The "Anatomic Pathology Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
• Thermo Fisher Scientific, Agilent Technologies, F. Hoffmann-La Roche Ltd., Sakura Finetek, Danaher Corporation, Hologic, Inc., Merck KGaA, Bio SB, Becton, Dickinson and Company, and Diapath S.p.A.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Anatomic Pathology Market Key Developments

• In September 2022, Epredia's parent company, PHC Holdings Corporation, strategically expanded its presence in Europe by acquiring anatomical pathology suppliers Microm Microtech France and Laurypath.
• In July 2022, BillionToOne, a United States-based company, launched its first oncology liquid biopsy products, Northstar Select and Northstar Response.
• In June 2022, Roche introduced the VENTANA DP 600 slide scanner, designed for digital pathology. This innovative technology is employed in anatomic pathology and bolsters patient care through precise diagnostics.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ANATOMIC PATHOLOGY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ANATOMIC PATHOLOGY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ANATOMIC PATHOLOGY MARKET, BY PRODUCT AND SERVICE

• 5.1 Overview
• 5.2 Instruments
• 5.3 Consumables
• 5.4 Services

6 GLOBAL ANATOMIC PATHOLOGY MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Disease Diagnosis
• 6.3 Drug Discovery and Development
• 6.4 Others

7 GLOBAL ANATOMIC PATHOLOGY MARKET, BY END-USER

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Diagnostic Laboratories
• 7.4 Research Laboratories
• 7.5 Others

8 GLOBAL ANATOMIC PATHOLOGY MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL ANATOMIC PATHOLOGY MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Thermo Fisher Scientific
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Agilent Technologies
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 F. Hoffmann-La Roche Ltd.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Sakura Finetek
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Danaher Corporation
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Hologic, Inc.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Merck KGaA
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Bio SB
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Becton, Dickinson and Company
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Diapath S.p.A.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research